Biotech commercialization playbook: lessons from BIO 2026 on scaling globally

Emerging biotech companies are rethinking how they bring their innovations to global markets. Insights from BIO 2026 point to a shift away from the traditional choice between licensing and building a fully integrated global organization, with more companies exploring independent and hybrid commercialization models.

In this article for Pharmaphorum Kirsten Detrick, Chief Representative USA at Basel Area Business & Innovation, explores why access to experienced talent and the right life sciences ecosystem can be critical to making these models work. With more than 33,000 life sciences professionals and deep expertise across commercialization functions, the Basel Area offers emerging biotechs an established base from which to launch and scale in Europe.